Showing 15 posts of 23 posts found.

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023
Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …


Janssen CLL treatment combination sees success in trials

June 14, 2021
Sales and Marketing CLL, Janssen

Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …


NICE approves Imbruvica for second-line leukaemia treatment

January 26, 2017
Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …


Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …


AbbVie, Janssen’s Imbruvica gets European approval to teat CLL

May 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, CLL, drug trial, regulation

AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. …


Novartis seeks expanded Arzerra use in US

March 11, 2016
Research and Development Arzerra, CLL, FDA, Genmab, Novartis

Novartis has submitted a supplemental Biologics License Application (sBLA) to the US FDA for the use of Arzerra (ofatumumab) in …


Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …


Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

Abbvie and Roche report success in Phase II leukaemia trial

August 13, 2015
Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax

AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …

ASCO image

ASCO 2015 roundup: immuno-oncology hits its stride

June 8, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, BMS, CLL, pdl1

One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks …

Roche logo

NICE signs-off Roche’s Gazyvaro for leukaemia

June 2, 2015
Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia

NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …

GSK image

NICE backs GSK’s leukaemia drug Arzerra following price cut

November 4, 2014
Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia

NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …

Roche image

Roche and Pharmacyclics agree leukaemia pact

October 17, 2014
Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia

Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …

Roche image

Roche falls foul of NICE rules, again

October 3, 2014
Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology

Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …

Zydelig image

Gilead’s blood cancer pill approved in Europe

September 22, 2014
Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig

Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …

Latest content